Latest posts tagged with #ASCO24 on Bluesky
@ascocancer.bsky.social Proud to be an ASCO member since 2023 🙌 @listenandcare.bsky.social new pts.
4/100 FASCO points earned | 96 to go #IntegrativeOncology voice at #ASCO24, #ASCO25 & Breakthrough 2024
Let’s keep pushing for equity, science, & shared outcomes.
#FASCOgoal #DrDJ #FABNOinTraining
Wrapping up #ASCO24 with this thought: let’s get more people under the survival curve and lift it up - it might be prolonged survival, it might even be cure. Every moment counts.
May we all walk into our post ASCO lives inspired ✨ 📈 @ascocancer.bsky.social @aspire-cop.bsky.social
Desmoplastic melanoma exquisitely sensitive to PD1 monotherapy, with 3 doses in resectable disease resulting in pCR 57% -Kari Kendra @ohiostatemed.bsky.social #ASCO24 #rarecancers @ascocancer.bsky.social
Dear Colleagues at #ASCO24, Do you Follow @OncoAlert 🚨?
Great! What about your colleagues.
Give them a tip and let's all keep each other informed on all the great Science out of Chicago in REAL TIME OncoAlert...For Colleagues....By Oncology Colleagues oncoalert360.com
This was a peak 🗻 moment of #ASCO24 for me. As much as I love @pallonccop.bsky.social 💻 connects, nothing beats an inperson event! Hope to see you all there! #ASCO25
@ascocancer.bsky.social
@crisbergerot.bsky.social
@tingtingzhang.bsky.social
@mazietsangmd.bsky.social
@darcyburbage.bsky.social
Oncologists—
The @ascocancer.bsky.social #ASCO24 #IDEA awardees are conducting a study to understand and identify barriers, opportunities, and strategies to improve evidence-based cancer care globally. Take a quick survey here:
forms.office.com/pages/respon...
Cc. @oncoalert.bsky.social
🎥 In this interview, Dr. Tiffany Sia from Memorial Sloan Kettering Cancer Center discusses her research on the germline landscape of ovarian cancer, focusing on elderly patients.
@mskcancercenter.bsky.social @ascocancer.bsky.social
oncodaily.com/dialogues/as...
#Cancer #ASCO24 #Health #OncoDaily
ASCO24 Updates: Dr. Tycel Phillips on Glofitamab in Mantle Cell Lymphoma
oncodaily.com/dialogues/24...
#Cancer #CancerResearch #Medicine #Health #ASCO #ASCO24 #Lymphoma #BloodCancer #Oncology #OncoDaily
Mesothelioma Guideline Updates from ASCO 2024: Key Advances in Diagnosis and Treatment
@ascocancer.bsky.social
oncodaily.com/oncolibrary/...
#ASCO #ASCO24 #Cancer #CancerCare #Medicine #CancerResearchGuidelines #Mesothelioma #Health #MesotheliomaGuidelines #OncoDaily #Oncology
Dr Greer describes the pivotal #REACHPC trial showing that #telehealth 💻 delievery of #pallonc improves symptoms while increasing access. Amazing to see this grace the Plenary stage of both @aahpm.bsky.social #hapc25 AND @ascocancer.bsky.social #ASCO24. My #supponc heart is full ❤️
TKIs Look to Solidify a Role Alongside T-DXd in the Second-Line HER2-Mutant NSCLC Setting @ascocancer.bsky.social @iaslc.bsky.social #ASCO24 #ESMOASIA24 #WCLC24 #lcsm #oncology
www.onclive.com/view/tkis-lo...
ASCO24 Updates: Delphine Chen on Radiopharmaceutical Imaging and Therapy Innovations
oncodaily.com/dialogues/as...
#ASCO #ASCO24 #ASCO24updates #Cancer #OncoDaily #Oncology #Medicine #Health
ASCO24 Updates: Alexis LeVee on Pembrolizumab and Microbiome in Breast Cancer
@ascocancer.bsky.social
oncodaily.com/dialogues/as...
#ASCO #ASCO24 #ASCO24Updates #Cancer #OncoDaily #OncoDailyASCO24Updates #Oncology #Medicine #Health #BCSM
No 8: BL-B01D1 EGFR X HER3 ADC
BL-B01D1 is a pivotal ADC targeting both EGFR and HER3, carrying a Topo1 inhibitor as a payload, with a DAR of 8. Achieved 63.2% ORR in #EGFRmut NSCLC pts with a median of 3 prior treat lines! Presented by Zang et al. in #ASCO24. 57% Gr>=3 TRAEs
#ASCO24 is mentioned! But will continue to try my best to give credit where possible.
🩸AML Treatment (simplified)
Here’s a nice general framework to treatment in AML!
#hemesky #hemeonc #oncsky #medsky #AML #leukemia #ASCO24
Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites
oncodaily.com/science/bisp...
#AdvancedBreastCancer #ColorectalCancer #M701 #GastricCancer #LungCancer #OvarianCancer #Antibody #ASCO24 #BispecificAntibody #Catumaxomab #EpCAM #ESMO #Immunotherapy#TargetedOncology
ASCO2024 Updates: Mark Markowski on AI Biomarkers in Prostate Cancer
oncodaily.com/dialogues/as...
@ascocancer.bsky.social
#AI #Artera #AIASCO #ASCO24 #ASCO24Updates #OncoDaily #ProstateCancer #Medicine #Health
I’m glad you were there! You just reminded me I never posted this photo with @hemoncwarner.bsky.social from #ASCO24!
Will you be going in 2025???
Welcome #pallonc #supponc folks to the official Blue Sky account for ASCO supported #PallOncCoP. Please follow for official Zoom meeting events, in-person conference meet ups like pic #ASCO24 and sharing the latest science in comfort and cure.
Working on the #ASCO #SCLC guidelines, published in 2023, was disheartening, but working on the rapid update (based on #ASCO24 data) left me emotional.
This update represents hope & progress for patients who have waited far too long. ascopubs.org/doi/10.1200/...
#LCSM
Can we still do Throw Back Thursdays over there?!
Tossing it way back to #ASCO24 and the Advocacy Lounge where we talked about being grateful for treatment advances AND wanting more focus on, and more access to, supportive care to #MakeCancerLessShitty
#PallOnc #hapc #SuppOnc #bcsm #crcsm #gyncsm
Basking in the #ASCO24 glow. Lesson learned ♾️ but 2 💡:
Find your #tribe where you are more than seen, but known
Also take someone with you
#BowTieFriday
@docwithbowtie.bsky.social
@ctsinclair.bsky.social
@engagetheo.bsky.social
@pinkprincess.bsky.social
CanSky MedSky hapc hpm
Proud to present our latest RNA- and AI-based #liquidbiopsy research at #ASCO24! #earlydetection #lifeatexai #MRD
For those of us in the US, who may complain about our patient portals, we have it WAY better than Ireland - no portals, pushback when asking for a copy of notes/test results. @SiobhanGaynor here at #ASCO24 with a poster showing patients want this info!!
Always love seeing advocate extraordinaire @MammaMiaMagazin and oncologist extraordinaire @nlinmd! #ASCO24
There were genomic differences between the races and, again, an abhorrent 50% difference in OS between the races. We MUST evaluate and treat all patients equitably, and we MUST offer clinical trials to everyone! #ASCO24
Wash U fellow @Podanymd speaking on racial differences and inequities. Black people with a PIK3CA mutation were given PIK3CA directed therapy only 6% of the time vs 29% in white people 😳. THIS IS ALMOST CRIMINAL! We must do better to stamp out racism in medicine. #ASCO24
PFS was significantly better in people who had the Y537S mutation. This was a heavily pretreated population so H3B-6545 bears watching. #ASCO24
